Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

GeeJoon Apr. 25 at 4:05 AM

$CANF price target before 20 in 1 rs... - HCW: $360 - D.BORAL: $220 - AGP: $90 https://d1io3yog0oux5.cloudfront.net/_b62815b7d63b1992fa7579cb429920eb/canfite/db/168/3165/pdf/2025-11-21+Can-fite+Fact+Sheet.pdf

0 · Reply

Farhas80 Apr. 21 at 7:27 PM

$CANF keep hitting 52 weeks low and still no news or data. Management just unbelievable.

0 · Reply

GeeJoon Apr. 19 at 11:07 PM

$CANF the efficacy data of pancreatic cancer p2a trial is very likely to be annonced during ASCO meeting May 29 - June 2, 2026

0 · Reply

GeeJoon Apr. 19 at 5:11 PM

$CANF street view on google map

0 · Reply

GeeJoon Apr. 18 at 3:24 PM

$CANF Q2 has gone 20%, interim result of psoriasis P3 is incoming, hopefully would change the valuation of this company

0 · Reply

Peaceouty Apr. 17 at 10:31 PM

$CANF Scam bitches leeching the doomed phase 3 to the max.

0 · Reply

GeeJoon Apr. 17 at 5:59 PM

$CANF 6/6... The Gospel of the hairy kids! Safe medicine is the most important In the past, dogs with joint pain can only take a bunch of anti-inflammatory drugs or injections with side effects. Now there is a chance to use new oral drugs that are human-grade and have no serious side effects. As the owner, I will definitely raise my hands "human medicine and animal use" is really a good business! Taking drugs that have been tested on humans to pets not only saves a lot of time in research and development, but also avoids the bargaining pressure of human health care, this business model is a super blue ocean for biotech companies. The spending power of the pet economy has surpassed imagination Seeing that this drug is estimated to generate more than $400 million in annual revenue, we know that people are raising pets as real children now, and future "pet precision medicine" will definitely become the next must for technology and biotech.

0 · Reply

GeeJoon Apr. 17 at 5:57 PM

$CANF 5/6... Technical analysis short review: From the perspective of industry strategy and technology transfer, Can-Fite’s layout is a perfect demonstration of asset reuse in the biopharmaceutical chain. Turning the drug "dimension reduction" that already has a large amount of human clinical data and a solid safety foundation to the veterinary market can greatly reduce the time and sunk costs of early lead drug development. In addition, the companion animal medicine market is showing strong rigid demand and the field enjoys extremely high pricing rights free from human health care drug pricing policy. This not only provides biotech companies with new ways to develop pipeline realization, but also reflects the long-term structural trend that the overall healthcare supply chain is actively spilling cutting-edge human pharmaceutical technology to the pet blue ocean market.

0 · Reply

GeeJoon Apr. 17 at 5:56 PM

$CANF 4/6... Over $300 million commercialization deal and blue ocean potential The development of this drug is based on a licensing model of "R&D and Commercialization Division". With Vetbiolix covering development costs and follow-up regulatory activities, Can-Fite expects to receive up to $325 million in payments (including advances, milestones and royalties) over the next decade if it is successfully commercialized. Industry forecasts point out that if Piclidenoson goes public in 2029, it is expected to capture 6 percent of the global companion animal arthritis market by 2034, peak sales will look at $445 million.

0 · Reply

GeeJoon Apr. 17 at 5:56 PM

$CANF 3/6... Rigorous Clinical Data Validation: Double-Blind Controlled Trial and Standardized Assessment This Phase II clinical trial involved 118 dogs with the disease and lasted for 90 days. The trial design employed the industry-standard Liverpool Canine Osteoarthritis Questionnaire (LOAD) and the Visual Analogue Scale (VAS), combining the perspectives of both pet owners and veterinarians to assess clinical efficacy. Preliminary data is expected to be released in the third quarter of 2026, which will serve as crucial data support for subsequent global commercial licensing.

0 · Reply

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

Mon, 30 Mar 2026 07:20:00 -0400 - 26 days ago

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Thu, 26 Mar 2026 09:27:00 -0400 - 4 weeks ago

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

2026-03-17T13:28:03.000Z - 5 weeks ago

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

Tue, 17 Mar 2026 07:47:00 -0400 - 5 weeks ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

2026-03-04T16:50:16.000Z - 7 weeks ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Wed, 04 Mar 2026 10:07:28 -0500 - 7 weeks ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

2026-03-04T12:34:33.000Z - 7 weeks ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

Wed, 04 Mar 2026 07:00:00 -0500 - 7 weeks ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

2026-02-17T12:36:34.000Z - 2 months ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-09T12:30:05.000Z - 2 months ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-05T12:33:49.000Z - 2 months ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-01-20T12:37:35.000Z - 3 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2025-12-23T22:55:20.000Z - 4 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:25:23.000Z - 4 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

Tue, 23 Dec 2025 16:46:00 -0500 - 4 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

2025-12-17T13:30:15.000Z - 4 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-16T15:29:50.000Z - 4 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

Tue, 16 Dec 2025 09:19:00 -0500 - 4 months ago

Can-Fite Provides Update on Clinical and Financial Status

2025-11-24T12:30:24.000Z - 5 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-20T12:42:31.000Z - 5 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

Thu, 20 Nov 2025 07:00:00 -0500 - 5 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

2025-11-18T20:00:37.000Z - 5 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

2025-11-18T12:30:20.000Z - 5 months ago

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

2025-11-04T12:01:46.000Z - 6 months ago

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

2025-09-16T12:32:06.000Z - 7 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

2025-09-15T12:40:09.000Z - 7 months ago

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

Thu, 28 Aug 2025 08:47:00 -0400 - 8 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Wed, 30 Jul 2025 07:04:00 -0400 - 9 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Mon, 28 Jul 2025 12:24:00 -0400 - 9 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Mon, 28 Jul 2025 07:00:00 -0400 - 9 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Thu, 17 Apr 2025 08:55:00 -0400 - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Mon, 14 Apr 2025 14:28:00 -0400 - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Thu, 20 Mar 2025 09:45:00 -0400 - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Wed, 19 Mar 2025 09:00:00 -0400 - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mon, 03 Mar 2025 06:00:00 -0500 - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mon, 10 Feb 2025 07:10:00 -0500 - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Wed, 05 Feb 2025 07:00:00 -0500 - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Mon, 30 Dec 2024 07:00:00 -0500 - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Fri, 22 Nov 2024 09:00:00 -0500 - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mon, 11 Nov 2024 07:00:00 -0500 - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Mon, 04 Nov 2024 07:08:00 -0500 - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Fri, 18 Oct 2024 09:06:00 -0400 - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Wed, 09 Oct 2024 07:00:00 -0400 - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Mon, 16 Sep 2024 07:00:00 -0400 - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Thu, 29 Aug 2024 08:15:00 -0400 - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

May 29, 2024, 7:00 AM EDT - 2 years ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 27, 2024, 7:00 AM EDT - 2 years ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 23, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 13, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 10, 2024, 9:00 AM EDT - 2 years ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

May 9, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Feb 28, 2024, 7:00 AM EST - 2 years ago

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

GeeJoon Apr. 25 at 4:05 AM

0 · Reply

Farhas80 Apr. 21 at 7:27 PM

$CANF keep hitting 52 weeks low and still no news or data. Management just unbelievable.

0 · Reply

GeeJoon Apr. 19 at 11:07 PM

$CANF the efficacy data of pancreatic cancer p2a trial is very likely to be annonced during ASCO meeting May 29 - June 2, 2026

0 · Reply

GeeJoon Apr. 19 at 5:11 PM

$CANF street view on google map

0 · Reply

GeeJoon Apr. 18 at 3:24 PM

$CANF Q2 has gone 20%, interim result of psoriasis P3 is incoming, hopefully would change the valuation of this company

0 · Reply

Peaceouty Apr. 17 at 10:31 PM

$CANF Scam bitches leeching the doomed phase 3 to the max.

0 · Reply

GeeJoon Apr. 17 at 5:59 PM

0 · Reply

GeeJoon Apr. 17 at 5:57 PM

0 · Reply

GeeJoon Apr. 17 at 5:56 PM

0 · Reply

GeeJoon Apr. 17 at 5:56 PM

0 · Reply

GeeJoon Apr. 17 at 5:53 PM

$CANF 2/6... Breaking through traditional therapy side effects: first oral A3 adenosine receptor agonist Canine arthritis currently relies heavily on non-steroidal anti-inflammatory drugs (NSAIDs) or injectable disease regulation drugs, often with significant side effects. Piclidenoson is a first-of-its-kind A3 adenosine receptor agonist originally developed for human inflammatory diseases such as dry acne and has completed Phase 3 trials in humans. Its shift to the field of veterinary medicine promises to provide safer and effective “oral” alternatives that improve dog mobility and reduce pain from the underlying mechanism.

0 · Reply

GeeJoon Apr. 17 at 5:53 PM

$CANF 1/6... Pet medical 100 billion blue oceans! New breakthrough in "human medicine and animal use", Can-Fite oral arthritis medicine is moving to commercialization With the rise and aging of the pet economy, the medical needs of companion animals are expanding rapidly. Biotech company Can-Fite BioPharma and its partner Vetbiolix have announced that Piclidenoson, a new oral drug for dog osteoarthritis, has completed recruitment for the second phase of clinical trial. This move not only marks a key step in the commercial transformation of “human medicine” but also reveals the vast economic potential of the pet medicine market. These 3 key industry dynamics and clinical designs reveal the latest path to the cross-border layout of biotechs:

0 · Reply

GeeJoon Apr. 16 at 2:30 PM

$CANF namodenoson, efficacy data expected in Q3 2026, 20 patients enrolled from late 2024 to Jan 2026, 1/3 patients still alive, unlikely to pass 50% OS at 12 months, 6.7m market cap $RVMD daraxonrasib, 64% OS rate at 12 months, median OS 13.2 months, 30.2b market cap $IMRX atebimetinib, 64% OS rate at 12 months, median PFS 8.5 months, 371.7m market cap

3 · Reply

GeeJoon Apr. 14 at 6:13 PM

$CANF I wonder if Namodenoson is as good as daraxonrasib from Revolution in treating pancreatic cancer...the market cap of $RVMD is 27b now after announcing its success in P3 trial... - doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy. - lived for 13.2 months versus 6.7 months under chemotherapy, an increase of 6.5 months.

0 · Reply

GeeJoon Apr. 13 at 12:59 AM

$CANF if you invested $100 into CANF at the very beginning, your investment will turn to 3 cents today...

0 · Reply

GeeJoon Apr. 13 at 12:36 AM

$CANF what this company creating is history low...look how those evil iraelis diluted shares...negative 99.97% all time wtf

0 · Reply

GeeJoon Apr. 10 at 12:30 AM

$CANF every day there are idiots dumping at the close of market to drag the sp down...

0 · Reply

GeeJoon Apr. 9 at 1:50 PM

$CANF 2026 will be a harvest year for CANF after 20 years of shit, any catalysts will make this shit 100x - Qx: pancreatic cancer p2a result - Q2: psoriasis p3 interim result - Q3: MASH p2b result - Q3: dogs osteoarthritis p2 result - Q4: liver cancer HCC CPB7 p3 interim result

0 · Reply

RobertKalermen Apr. 6 at 6:42 PM

$CANF For those who criticized me when I called for a low of $2.85 after last qtr. earnings (ahem), you'll be happy to know that now is the time to buy..It pays to be a PhD that played a key role in building Amgen's early to mid success. The valuation and internal clinical studies now line up..

0 · Reply

GeeJoon Apr. 6 at 2:16 PM

$CANF it is ridiculous market cap of $DRUG is 700m without completing p2, but $CANF have 2 ongoing p3 and only worth 6m...

0 · Reply

bongpal Apr. 6 at 6:45 AM

$CANF give us a big pump!!

0 · Reply

laaarsas Apr. 5 at 9:16 PM

$CANF what is going on here?

0 · Reply

Market Cap	1.91M
Revenue (ttm)	410,000.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,397.56%
Debt to Equity Ratio	0.00

Volume	18,500
Avg Vol	836,628
Day's Range	N/A - N/A
Shares Out	655,000.00
Stochastic %K	11%
Beta	1.06
Analysts	Sell
Price Target	$4.50